ATE298742T1 - Zykloalkenylsulfonamidderivate - Google Patents

Zykloalkenylsulfonamidderivate

Info

Publication number
ATE298742T1
ATE298742T1 AT02733989T AT02733989T ATE298742T1 AT E298742 T1 ATE298742 T1 AT E298742T1 AT 02733989 T AT02733989 T AT 02733989T AT 02733989 T AT02733989 T AT 02733989T AT E298742 T1 ATE298742 T1 AT E298742T1
Authority
AT
Austria
Prior art keywords
cycloalkenylsulfonamide
derivatives
useful
psychiatric
patient
Prior art date
Application number
AT02733989T
Other languages
English (en)
Inventor
Buddy Eugene Cantrell
Dennis Michael Zimmerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE298742T1 publication Critical patent/ATE298742T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04Diamides of sulfuric acids
    • C07C307/08Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/07Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02733989T 2001-05-30 2002-05-17 Zykloalkenylsulfonamidderivate ATE298742T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29442801P 2001-05-30 2001-05-30
PCT/US2002/011895 WO2002098847A1 (en) 2001-05-30 2002-05-17 Cycloalkenylsulfonamide derivatives

Publications (1)

Publication Number Publication Date
ATE298742T1 true ATE298742T1 (de) 2005-07-15

Family

ID=23133381

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02733989T ATE298742T1 (de) 2001-05-30 2002-05-17 Zykloalkenylsulfonamidderivate

Country Status (7)

Country Link
US (1) US20040157817A1 (de)
EP (1) EP1395550B1 (de)
JP (1) JP2004529978A (de)
AT (1) ATE298742T1 (de)
CA (1) CA2447746A1 (de)
DE (1) DE60204882D1 (de)
WO (1) WO2002098847A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
MX2007001678A (es) * 2004-08-09 2007-04-12 Glaxo Group Ltd Compuestos que potencian el receptor de glutamato y sus usos en medicina.
TWI446908B (zh) * 2005-06-06 2014-08-01 Lilly Co Eli Ampa受體強化劑
DE602006003661D1 (de) 2005-06-06 2008-12-24 Lilly Co Eli Ampa-rezeptoren-verstärker
JP5014334B2 (ja) * 2005-10-06 2012-08-29 イーライ リリー アンド カンパニー Ampa受容体増強剤
GB0602560D0 (en) * 2006-02-08 2006-03-22 Glaxo Group Ltd Compounds
EP2356099A1 (de) * 2008-10-08 2011-08-17 Pfizer Inc. Tetrahydorfuranylsulfonamide zur verwendung als ampa-modulatoren bei der behandlung von zns-erkrankungen
WO2014201411A1 (en) 2013-06-13 2014-12-18 Veroscience Llc Compositions and methods for treating metabolic disorders
WO2018009256A1 (en) 2016-03-29 2018-01-11 Respirerx Pharmaceuticals, Inc. Compositions and methods for treating attention deficit disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
DE69917278T2 (de) * 1998-07-31 2005-05-19 Eli Lilly And Co., Indianapolis Heterocyclyl sulphonamid derivate
US6358981B1 (en) * 1998-07-31 2002-03-19 Eli Lilly And Company Sulphonamide derivatives
US6500865B1 (en) * 1998-07-31 2002-12-31 Eli Lilly And Company Sulfonamide derivatives
CA2338862A1 (en) * 1998-07-31 2000-02-10 Dennis Michael Zimmerman Alkenyl sulphonamide derivatives
US6639107B1 (en) * 1999-12-08 2003-10-28 Eli Lilly And Company Cyclopentyl sulfonamide derivatives

Also Published As

Publication number Publication date
WO2002098847A1 (en) 2002-12-12
EP1395550B1 (de) 2005-06-29
EP1395550A1 (de) 2004-03-10
CA2447746A1 (en) 2002-12-12
JP2004529978A (ja) 2004-09-30
DE60204882D1 (de) 2005-08-04
US20040157817A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
IS6922A (is) Heterófjölhringjaefnasambönd og notkun þeirra semmetabótrópísk mótlyf gegn glútamat viðtökum
UA87856C2 (ru) Алкильные производные как модуляторы метаботропных рецепторов глутамата
DE69820632D1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
MY127686A (en) Monofluoroalkyl derivatives
ATE272617T1 (de) Sulfonamid-derivate
WO2000006083A3 (en) Sulfonamide derivatives
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
WO2002014294A3 (en) Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
WO2002014275A3 (en) Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
ATE298742T1 (de) Zykloalkenylsulfonamidderivate
DE50201565D1 (de) 2-thio-subsituierte imidazolderivative und ihre verwendung in der pharmazie
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
DK1399438T3 (da) Hidtil ukendte heteroarylderivater samt fremstilling og anvendelse heraf
DE502004007387D1 (de) Triazolverbindungen und ihre therapeutische verwendung
YU22802A (sh) Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina
MY136138A (en) Hexacyclic compounds
SI1603877T1 (sl) Novi derivati aminopiridina kot antagonisti mGiuR5
DK1368336T3 (da) Thiophensubstituerede aminderivater som GlyT-1-inhibitorer
MXPA03011766A (es) Novedosos derivados de indol.
DE60203740D1 (de) Luminacine analoge und deren verwendung
EA200501053A1 (ru) Производные 1,2,4-триаминобензола, пригодные для лечения расстройств центральной нервной системы

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties